These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

845 related articles for article (PubMed ID: 28840314)

  • 41. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders.
    Sato DK; Callegaro D; Lana-Peixoto MA; Waters PJ; de Haidar Jorge FM; Takahashi T; Nakashima I; Apostolos-Pereira SL; Talim N; Simm RF; Lino AM; Misu T; Leite MI; Aoki M; Fujihara K
    Neurology; 2014 Feb; 82(6):474-81. PubMed ID: 24415568
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases.
    Mader S; Kümpfel T; Meinl E
    Curr Opin Neurol; 2020 Jun; 33(3):362-371. PubMed ID: 32304439
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
    Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
    J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD.
    Arru G; Sechi E; Mariotto S; Zarbo IR; Ferrari S; Gajofatto A; Monaco S; Deiana GA; Bo M; Sechi LA; Sechi GP
    J Neuroimmunol; 2020 Jan; 338():577110. PubMed ID: 31715457
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Hacohen Y; Mankad K; Chong WK; Barkhof F; Vincent A; Lim M; Wassmer E; Ciccarelli O; Hemingway C
    Neurology; 2017 Jul; 89(3):269-278. PubMed ID: 28615429
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. What You Need to Know About AQP4, MOG, and NMOSD.
    Prasad S; Chen J
    Semin Neurol; 2019 Dec; 39(6):718-731. PubMed ID: 31847043
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.
    Mariotto S; Gajofatto A; Batzu L; Delogu R; Sechi G; Leoni S; Pirastru MI; Bonetti B; Zanoni M; Alberti D; Schanda K; Monaco S; Reindl M; Ferrari S
    Neurology; 2019 Nov; 93(20):e1867-e1872. PubMed ID: 31645473
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets?
    Mader S; Jeganathan V; Arinuma Y; Fujieda Y; Dujmovic I; Drulovic J; Shimizu Y; Sakuma Y; Stern JNH; Aranow C; Mackay M; Yasuda S; Atsumi T; Hirohata S; Diamond B
    Arthritis Rheumatol; 2018 Feb; 70(2):277-286. PubMed ID: 29073350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
    Flanagan EP; Weinshenker BG; Krecke KN; Lennon VA; Lucchinetti CF; McKeon A; Wingerchuk DM; Shuster EA; Jiao Y; Horta ES; Pittock SJ
    JAMA Neurol; 2015 Jan; 72(1):81-7. PubMed ID: 25384099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
    Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
    Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 54. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders.
    Yang L; Li H; Xia W; Quan C; Zhou L; Geng D; Li Y
    Eur Radiol; 2020 Mar; 30(3):1470-1479. PubMed ID: 31748853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
    Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
    Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Brain lesion distribution criteria distinguish demyelinating diseases in China.
    Cai MT; Zhang YX; Zheng Y; Yang F; Fang W; Shen CH; Ding MP
    Ann Clin Transl Neurol; 2019 Oct; 6(10):2048-2053. PubMed ID: 31566925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease.
    Lechner C; Baumann M; Hennes EM; Schanda K; Marquard K; Karenfort M; Leiz S; Pohl D; Venkateswaran S; Pritsch M; Koch J; Schimmel M; Häusler M; Klein A; Blaschek A; Thiels C; Lücke T; Gruber-Sedlmayr U; Kornek B; Hahn A; Leypoldt F; Sandrieser T; Gallwitz H; Stoffels J; Korenke C; Reindl M; Rostásy K
    J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):897-905. PubMed ID: 26645082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of serostatus in pediatric neuromyelitis optica spectrum disorders: A nationwide multicentric study.
    Solmaz I; Öncel IH; Konuşkan B; Erol I; Orgun LT; Yılmaz Ü; Ünalp A; Atasoy E; Aksoy E; Yılmaz D; Öztürk M; Karaca NB; Yılmaz S; Yiş U; Dündar NO; Parlak Ş; Vural A; Günbey C; Anlar B
    Mult Scler Relat Disord; 2023 Sep; 77():104847. PubMed ID: 37393803
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive Value of Serum Antibodies and Point Mutations of AQP4, AQP1 and MOG in A Cohort of Spanish Patients with Neuromyelitis Optica Spectrum Disorders.
    García-Miranda P; Morón-Civanto FJ; Martínez-Olivo MDM; Suárez-Luna N; Ramírez-Lorca R; Lebrato-Hernández L; Lamas-Pérez R; Navarro G; Abril-Jaramillo J; García-Sánchez MI; Casado-Chocán JL; Uclés-Sánchez AJ; Romera M; Echevarría M; Díaz-Sánchez M
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort.
    Dauby S; Dive D; Lutteri L; Andris C; Hansen I; Maquet P; Lommers E
    Acta Neurol Belg; 2022 Feb; 122(1):135-144. PubMed ID: 34097296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.